Innate Pharma (IPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innate Pharma (IPH) has a cash flow conversion efficiency ratio of 0.995x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-21.59 Million ≈ $-25.24 Million USD) by net assets (€-21.70 Million ≈ $-25.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Innate Pharma to measure how many days the company can operate on defensive assets alone.
Innate Pharma - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Innate Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Innate Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innate Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C-Media Electronics
TWO:6237
|
0.005x |
|
Distribuidora de Gas Cuyana SA
BA:DGCU2
|
0.138x |
|
ATW Technology Inc
TWO:8097
|
-0.004x |
|
John Hancock Investors Closed Fund
NYSE:JHI
|
0.068x |
|
RheinLand Holding AG
DU:RLV
|
N/A |
|
Eidesvik Offshore ASA
OL:EIOF
|
0.186x |
|
Prime Office A/S
CO:PRIMOF
|
0.007x |
|
LK CHEM
KQ:489500
|
0.040x |
Annual Cash Flow Conversion Efficiency for Innate Pharma (2005–2025)
The table below shows the annual cash flow conversion efficiency of Innate Pharma from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see IPH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-21.70 Million ≈ $-25.37 Million |
€-52.76 Million ≈ $-61.68 Million |
2.431x | +411.38% |
| 2024-12-31 | €8.83 Million ≈ $10.33 Million |
€-6.90 Million ≈ $-8.06 Million |
-0.781x | -24.44% |
| 2023-12-31 | €51.90 Million ≈ $60.68 Million |
€-32.56 Million ≈ $-38.06 Million |
-0.627x | -77.35% |
| 2022-12-31 | €54.15 Million ≈ $63.31 Million |
€-19.15 Million ≈ $-22.39 Million |
-0.354x | +34.99% |
| 2021-12-31 | €107.44 Million ≈ $125.61 Million |
€-58.46 Million ≈ $-68.34 Million |
-0.544x | -63.81% |
| 2020-12-31 | €155.97 Million ≈ $182.35 Million |
€-51.81 Million ≈ $-60.57 Million |
-0.332x | -306.78% |
| 2019-12-31 | €217.42 Million ≈ $254.18 Million |
€34.92 Million ≈ $40.83 Million |
0.161x | +182.58% |
| 2018-12-31 | €167.24 Million ≈ $195.52 Million |
€-32.53 Million ≈ $-38.03 Million |
-0.195x | +65.21% |
| 2017-12-31 | €85.96 Million ≈ $100.49 Million |
€-48.06 Million ≈ $-56.19 Million |
-0.559x | -30.74% |
| 2016-12-31 | €86.17 Million ≈ $100.74 Million |
€-36.85 Million ≈ $-43.08 Million |
-0.428x | -114.82% |
| 2015-12-31 | €72.07 Million ≈ $84.25 Million |
€207.91 Million ≈ $243.07 Million |
2.885x | +1287.24% |
| 2014-12-31 | €74.63 Million ≈ $87.25 Million |
€-18.13 Million ≈ $-21.20 Million |
-0.243x | +10.74% |
| 2013-12-31 | €40.29 Million ≈ $47.10 Million |
€-10.97 Million ≈ $-12.82 Million |
-0.272x | +39.28% |
| 2012-12-31 | €23.36 Million ≈ $27.31 Million |
€-10.47 Million ≈ $-12.25 Million |
-0.448x | -191.92% |
| 2011-12-31 | €26.62 Million ≈ $31.13 Million |
€12.99 Million ≈ $15.18 Million |
0.488x | +221.55% |
| 2010-12-31 | €33.52 Million ≈ $39.18 Million |
€-13.45 Million ≈ $-15.72 Million |
-0.401x | -218.54% |
| 2009-12-31 | €47.12 Million ≈ $55.09 Million |
€-5.94 Million ≈ $-6.94 Million |
-0.126x | +64.67% |
| 2008-12-31 | €41.34 Million ≈ $48.33 Million |
€-14.74 Million ≈ $-17.23 Million |
-0.357x | -90.56% |
| 2007-12-31 | €49.61 Million ≈ $57.99 Million |
€-9.28 Million ≈ $-10.85 Million |
-0.187x | -3029.85% |
| 2006-12-31 | €56.37 Million ≈ $65.90 Million |
€360.00K ≈ $420.88K |
0.006x | +101.77% |
| 2005-12-31 | €20.07 Million ≈ $23.46 Million |
€-7.25 Million ≈ $-8.47 Million |
-0.361x | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more